{"nctId":"NCT02905266","briefTitle":"A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma","startDateStruct":{"date":"2016-10-27","type":"ACTUAL"},"conditions":["Melanoma"],"count":106,"armGroups":[{"label":"Nivolumab and Ipilimumab Concomitant Administration","type":"EXPERIMENTAL","interventionNames":["Biological: Nivolumab","Biological: Ipilimumab"]},{"label":"Nivolumab and Ipilimumab Sequential Administration","type":"EXPERIMENTAL","interventionNames":["Biological: Nivolumab","Biological: Ipilimumab"]}],"interventions":[{"name":"Nivolumab","otherNames":[]},{"name":"Ipilimumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Males and Females, ages 15 years â‰¥ of age (Except where local regulations and/or institutional policies do not allow for subjects \\< 18 years of age to participate)\n* Subjects must have been diagnosed with stage III or/and stage IV histologically confirmed melanoma that is unresectable or metastatic\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Subjects have not been treated by systemic anticancer therapy for unresectable or metastatic melanoma\n\nExclusion Criteria:\n\n* Subjects with active brain metastases or leptomeningeal metastases\n* Subjects with ocular melanoma\n* Subjects with active, known or suspected autoimmune disease\n\nOther protocol defined inclusion/exclusion criteria could apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Percentage of Participants Affected by AEs in the Narrow Scope MedDRA Anaphylactic Reaction SMQ","description":"This outcome describes the percentage of participants experiencing at least 1 AE in the MedDRA Anaphylactic Reaction narrow scope SMQ. The narrow scope SMQ is composed of a large list of terms, including (but not limited to) anaphylactic shock and reaction, shock and shock symptoms, and circulatory collapse, among the others.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Affected by Hypersensitivity/Infusion Reaction Select AEs","description":"This outcome describes the percentage of participants experiencing at least 1 AE in the Hypersensitivity/Infusion select AEs category. The select AEs consist of a list of preferred terms defined by the Sponsor and represent AEs with a potential immune-mediated etiology. The following 5 MedDRA preferred terms are included in the hypersensitivity/infusion reaction select AE category: Anaphylactic Reaction, Anaphylactic Shock, Bronchospasm, Hypersensitivity, and Infusion Related Reaction","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"9.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Affected by All Causality Grade 3 - 5 AEs","description":"This outcome describes the percentage of participants who experienced at least 1 AE of Grade 3 or higher defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.8","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Affected by Drug-related Grade 3 - 5 AEs","description":"This outcome describes the percentage of participants who experienced at least 1 Drug-related AE of Grade 3 or higher defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.5","spread":null},{"groupId":"OG001","value":"47.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration of Ipilimumab at End of Infusion (EOI)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.4","spread":"93.0"},{"groupId":"OG001","value":"61.5","spread":"72.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.8","spread":"134"},{"groupId":"OG001","value":"72.1","spread":"71.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.9","spread":"94.2"},{"groupId":"OG001","value":"84.6","spread":"104"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration of Nivolumab at End of Infusion (EOI)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":"77.3"},{"groupId":"OG001","value":"21.8","spread":"117"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":"122"},{"groupId":"OG001","value":"22.4","spread":"101"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.9","spread":"79.8"},{"groupId":"OG001","value":"27.4","spread":"79.9"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Trough Concentration of Ipilimumab","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":"30.2"},{"groupId":"OG001","value":"9.94","spread":"38.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":"36.9"},{"groupId":"OG001","value":"13.7","spread":"46.0"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Trough Concentration of Nivolumab","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.94","spread":"56.6"},{"groupId":"OG001","value":"2.75","spread":"65.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.50","spread":"44.6"},{"groupId":"OG001","value":"4.05","spread":"75.3"}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR)","description":"The ORR is defined as the proportion of participants with a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR). The BOR is defined as the best response designation, as determined by the investigator, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of subsequent anti-cancer therapy, whichever occurs first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.8","spread":null},{"groupId":"OG001","value":"60.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"PFS is defined as the time between the date of randomization and the first date of documented progression, as determined by the investigator, or death due to any cause, whichever occurs first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.25","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Affected by Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ)","description":"This outcome describes the percentage of participants experiencing at least 1 AE in the MedDRA Anaphylactic Reaction broad scope SMQ. Such AEs include any acute systemic reaction characterized by a large list of terms, including (but not limited to) pruritus, urticaria, flushing, hypotension, respiratory distress, and vascular insufficiency. It also includes other signs and symptoms such as asthma, choking sensation, coughing, sneezing, and difficulty breathing due to laryngeal spasm and/or bronchospasm. Less frequent clinical presentations are also captured and include hyperventilation, sensation of foreign body, and ocular edema.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":null},{"groupId":"OG001","value":"17.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":35,"n":53},"commonTop":["Diarrhoea","Asthenia","Pyrexia","Rash","Pruritus"]}}}